How long is a course of treatment with gilteritinib?

Gilteritinib is indicated for the treatment of FMS-like tyrosine kinase3 (FLT3)mutated adult patients with relapsed or refractory acute myeloid leukemia. The recommended dose in the instructions is 120 mg orally once daily until disease progression or toxicity is unacceptable. In the absence of disease progression or unacceptable toxicity, patients should receive treatment for at least6 months to allow time for clinical response.

Under normal circumstances, patients take giritinib for a review about one month. The fumarate form of giritinib, a receptor tyrosine kinase(RTKs) FMSlike tyrosine kinase3 (FLT 3; STK1FLK2), AXL(UFO; JTK11), anaplastic Lymphoma kinase (ALK; CD246) and leukocyte receptor tyrosine kinase (LTK), have potential anti-tumor activity. Upon administration, giritinib binds to and inhibits wild-type and mutant FLT3, AXL, ALK, and LTK. This may result in FLT3-, AXL-, ALK- and RTKs and reduction in proliferation of cancer cells overexpressing these RTKs. FLT3, AXL, ALK and LTK are overexpressed or mutated in a variety of cancer cell types and play key roles in tumor cell growth and survival. AcceptPatients treated with giritinib developed symptoms of differentiation syndrome, which may be fatal or life-threatening if left untreated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, hypotension, or renal insufficiency. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. There are many versions of generic drugs, priced at around three to four thousand per box. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.